Michael Lucas James
I have an extensive background in neuroanesthesia and neurointensive care and a special research interest in translational and clinical research aspects of intracerebral hemorrhage.
After completing residencies in neurology and anesthesiology with fellowships in neurocritical care, neuroanesthesia, and vascular neurology, I developed a murine model of intracerebral hemorrhage in the Multidisciplinary Neuroprotection Laboratories at Duke University. After optimization of the model, I have begun to pursue translatable mechanisms of modifying neuroinflammation after intracerebral hemorrhage to improve long-term functional recovery. In addition, I have used the model to evaluate the potential of several novel therapeutics for translation into human clinical trials.
While maintaining an active and productive laboratory, I am or have been a Principal Investigator on several clinical trials involving patients with intracerebral hemorrhage. As part of the Translational Acute Brain Injury Research Center at Duke University, I am, or have been, the Duke site-PI for large, multicenter trials funded by the NIH, including CLEAR-IVH, MISTIE, ERICH, and HI-Def studies. Further, I am leading smaller industry-sponsored trials and “home grown” projects in this patient population.
In addition to a research focus in intracerebral hemorrhage, I have an active clinical practice in neuroanesthesia. Our center consistently handles a high volume of neurovascular neurosurgical cases, which require neuroanesthesia subspecialization. This small group of neuroanesthesiologists handles patient care and research opportunities during the peri-operative period, as patients move between the emergency department, neurointensive care unit, operative suites, and neurointerventional suites. I am, or have been, Co-PI of several small, industry-sponsored neuroanesthesia device or therapeutic clinical trials.
Finally, I am fortunate to be part of a unique team of highly motivated and productive individuals that comprise a truly translational collaboration. This allows me to propel ideas from bench to bedside and the ability to reverse translate ideas from the bedside back to the bench. In summary, I have a demonstrated record of successful and productive research projects in areas of high relevance to intracerebral hemmorrhage.
Education and Training
- M.D., Louisiana State University, 1999
Selected Grants and Awards
- Novartis Phase II BAF312 in Stroke ICH
- HOBIT Trial
- NICO BrainPath Intracerebral Hemorrhage Evacuation Sample Analysis
- SETPOINT 2: A pragmatic trial to test the effectiveness of early vs. delayed percutaneous tracheostomy in patients with severe stroke and respiratory failure.
- Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST-3)
- CN105 to improve long-term recovery in models of intracerebral hemorrhage
- Intrepid- BMD-1111
- CN-105 Study
- Genetic and Environmental Risk Factors for Hemorrhagic Stroke
- Futility study of Deferoxamine Mesylate in Intracerebral Hemorrhage (i-Def)
- Dova Avatrombopag for Thrombocytopenia
- Xenon As A Therapeutic in Experimental Intracerebral Hemorrhage
- Cephalogics DOT 3.0 in Cerebral Vasospasm